CD3D has been reported as a potential biomarker for the response to ICIs and prognosis in cancers, including colon cancer and muscle-invasive bladder cancer (Klintman et al., 2016; Shi et al., 2019; Yang et al., 2020). This evidence concerns the gene CD3D and malignant colon neoplasm.